Qinjun Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qinjun Chu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Anmin Hu
Department of Anesthesia, Shenzhen Peoples Hospital, Shenzhen, China
1 shared publication Chen Liu
Biomedical Engineering Center, Shenzhen United Scheme Technology Company Limited, Shenzhen, Guangdong, China
1 shared publicationGao-Feng Zhan
Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publicationHai-Long Bing
Department of Anesthesiology and Perioperative Medicine, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China
1 shared publicationHailong Bing
1 shared publicationHui-Jie Li
Faculty of Applied Sciences, Macao Polytechnic University, Macao, China
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (11) , 1561
Perioperative Anxiety in Adults: A Narrative Review of Pathophysiology, Assessment, and Multimodal Management Strategies
Perioperative anxiety is a common psychophysiological stress response experienced by patients before and after surgery, with a global prevalence of approximately 48%. Its occurrence is influenced by multiple factors including age, sex, type of surgery, and psychosocial determinants. The underlying pathophysiological mechanisms are complex, involving multi-system interactions such as autonomic nervous system imbalance, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, dysfunction of limbic system neural circuits, and neuroinflammation. Current assessment strategies are evolving from sole reliance on psychological scales toward multimodal approaches incorporating objective biomarkers including heart rate variability, cortisol, and electroencephalography. Management paradigms have shifted from traditional pharmacological premedication to integrated systems encompassing structured patient education, digital health tools, neuromodulation techniques, and cognitive behavioral therapy. However, significant gaps persist regarding standardized screening protocols, biomarker validation, and targeted intervention pathways for high-risk populations. Future management is likely to require more individualized risk assessment and intervention selection. Biomarker-based risk prediction, artificial intelligence-assisted intervention decision-making, and the deep integration of digital therapeutics such as virtual reality with existing enhanced recovery pathways will be key directions for improving patient outcomes and recovery quality. This structured narrative review summarizes current evidence on perioperative anxiety in adults, focusing on epidemiology, pathophysiological mechanisms, assessment tools, biomarkers, and multimodal management strategies.
- 3 June 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (11) , 1561
Open AccessPerioperative Anxiety in Adults: A Narrative Review of Pathophysiology, Assessment, and Multimodal Management Strategies
Perioperative anxiety is a common psychophysiological stress response experienced by patients before and after surgery, with a global prevalence of approximately 48%. Its occurrence is influenced by multiple factors including age, sex, type of surgery, and psychosocial determinants. The underlying pathophysiological mechanisms are complex, involving multi-system interactions such as autonomic nervous system imbalance, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, dysfunction of limbic system neural circuits, and neuroinflammation. Current assessment strategies are evolving from sole reliance on psychological scales toward multimodal approaches incorporating objective biomarkers including heart rate variability, cortisol, and electroencephalography. Management paradigms have shifted from traditional pharmacological premedication to integrated systems encompassing structured patient education, digital health tools, neuromodulation techniques, and cognitive behavioral therapy. However, significant gaps persist regarding standardized screening protocols, biomarker validation, and targeted intervention pathways for high-risk populations. Future management is likely to require more individualized risk assessment and intervention selection. Biomarker-based risk prediction, artificial intelligence-assisted intervention decision-making, and the deep integration of digital therapeutics such as virtual reality with existing enhanced recovery pathways will be key directions for improving patient outcomes and recovery quality. This structured narrative review summarizes current evidence on perioperative anxiety in adults, focusing on epidemiology, pathophysiological mechanisms, assessment tools, biomarkers, and multimodal management strategies.
- Open Access
- 29 April 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Reinforcement learning based automated anesthesia system for gastrointestinal endoscopy with a multicenter randomized trial
The increasing demand for gastrointestinal endoscopic procedures, coupled with a global shortage of anesthesiologists, underscores the need for intelligent automation in anesthesia care. Reinforcement learning (RL) offers a promising strategy for autonomous anesthesia control, yet prospective clinical validation remains limited. We developed an RL-based automated anesthesia system for gastrointestinal endoscopy (AAS-GE) for automated ciprofol delivery and conducted a prospective, multicenter, randomized controlled trial across four centers in China between January 8 and August 27, 2025. Adults aged 18–65 years with American Society of Anesthesiologists physical status I–II undergoing gastrointestinal endoscopy were randomized 1:1 to receive either AAS-GE–controlled anesthesia or clinician-managed manual anesthesia. The primary outcome was the incidence of hypoxemia, defined as oxygen saturation below 92%, with secondary outcomes assessing hypoxemia severity, induction time, drug use, recovery, and adverse events. A total of 509 participants were included in algorithm development, and 418 were enrolled for clinical validation. The incidence of hypoxemia was comparable between groups (14.42 vs. 14.29%; odds ratio 1.01, 95% CI 0.59–1.75; P = 0.968), with no significant differences in secondary safety outcomes. AAS-GE achieved a shorter induction time (median 1.55 vs. 1.90 min; P < 0.001) without increasing total drug dose or recovery time. However, intraoperative body movement was more frequent in the AAS-GE group, consistent with lighter anesthesia depth. These results demonstrate the non-inferior safety and efficacy of AAS-GE compared with clinician management, supporting its potential to improve efficiency and standardize sedation care. Clinical registration: ClinicalTrials.gov on Feb. 26, 2025 (NCT06857344).
- 29 April 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Open AccessReinforcement learning based automated anesthesia system for gastrointestinal endoscopy with a multicenter randomized trial
The increasing demand for gastrointestinal endoscopic procedures, coupled with a global shortage of anesthesiologists, underscores the need for intelligent automation in anesthesia care. Reinforcement learning (RL) offers a promising strategy for autonomous anesthesia control, yet prospective clinical validation remains limited. We developed an RL-based automated anesthesia system for gastrointestinal endoscopy (AAS-GE) for automated ciprofol delivery and conducted a prospective, multicenter, randomized controlled trial across four centers in China between January 8 and August 27, 2025. Adults aged 18–65 years with American Society of Anesthesiologists physical status I–II undergoing gastrointestinal endoscopy were randomized 1:1 to receive either AAS-GE–controlled anesthesia or clinician-managed manual anesthesia. The primary outcome was the incidence of hypoxemia, defined as oxygen saturation below 92%, with secondary outcomes assessing hypoxemia severity, induction time, drug use, recovery, and adverse events. A total of 509 participants were included in algorithm development, and 418 were enrolled for clinical validation. The incidence of hypoxemia was comparable between groups (14.42 vs. 14.29%; odds ratio 1.01, 95% CI 0.59–1.75; P = 0.968), with no significant differences in secondary safety outcomes. AAS-GE achieved a shorter induction time (median 1.55 vs. 1.90 min; P < 0.001) without increasing total drug dose or recovery time. However, intraoperative body movement was more frequent in the AAS-GE group, consistent with lighter anesthesia depth. These results demonstrate the non-inferior safety and efficacy of AAS-GE compared with clinician management, supporting its potential to improve efficiency and standardize sedation care. Clinical registration: ClinicalTrials.gov on Feb. 26, 2025 (NCT06857344).
- Open Access
- 1 February 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (3) , 1700-1702
Monocytes in the brain–heart crosstalk control sleep under myocardial infarction
- 1 February 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (3) , 1700-1702
Open AccessMonocytes in the brain–heart crosstalk control sleep under myocardial infarction
- Open Access
- 22 July 2022
- Published by Springer Nature in Cell & Bioscience
- Vol. 12 (1) , 1-19
SENP6 induces microglial polarization and neuroinflammation through de-SUMOylation of Annexin-A1 after cerebral ischaemia–reperfusion injury
Background: Previous data have reported that Sentrin/SUMO-specific protease 6 (SENP6) is involved in ischaemic brain injury and induces neuronal apoptosis after cerebral ischaemia, but the role of SENP6 in microglia-induced neuroinflammation and its underlying mechanism remain poorly understood. This research systematically explored the function and potential mechanism of SENP6 in microglia-induced neuroinflammation after ischaemic stroke. Results: We first identified an increased protein level of SENP6 in microglia after cerebral ischaemia. Then, we demonstrated that SENP6 promoted detrimental microglial phenotype polarization. Specifically, SENP6-mediated de-SUMOylation of ANXA1 targeted the IκB kinase (IKK) complex and selectively inhibited the autophagic degradation of IKKα in an NBR1-dependent manner, activating the NF-κB pathway and enhancing proinflammatory cytokine expression. In addition, downregulation of SENP6 in microglia effectively reduced cocultured neuronal damage induced by ischaemic stroke. More importantly, we employed an AAV-based technique to specifically knockdown SENP6 in microglia/macrophages, and in vivo experiments showed that SENP6 inhibition in microglia/macrophages notably lessened brain ischaemic infarct size, decreased neurological deficit scores, and ameliorated motor and cognitive function in mice subjected to cerebral ischaemia surgery. Conclusion: We demonstrated a previously unidentified mechanism by which SENP6-mediated ANXA1 de-SUMOylation regulates microglial polarization and our results strongly indicated that in microglia, inhibition of SENP6 may be a crucial beneficial therapeutic strategy for ischaemic stroke. Graphical
- 22 July 2022
- Published by Springer Nature in Cell & Bioscience
- Vol. 12 (1) , 1-19
Open AccessSENP6 induces microglial polarization and neuroinflammation through de-SUMOylation of Annexin-A1 after cerebral ischaemia–reperfusion injury
Background: Previous data have reported that Sentrin/SUMO-specific protease 6 (SENP6) is involved in ischaemic brain injury and induces neuronal apoptosis after cerebral ischaemia, but the role of SENP6 in microglia-induced neuroinflammation and its underlying mechanism remain poorly understood. This research systematically explored the function and potential mechanism of SENP6 in microglia-induced neuroinflammation after ischaemic stroke. Results: We first identified an increased protein level of SENP6 in microglia after cerebral ischaemia. Then, we demonstrated that SENP6 promoted detrimental microglial phenotype polarization. Specifically, SENP6-mediated de-SUMOylation of ANXA1 targeted the IκB kinase (IKK) complex and selectively inhibited the autophagic degradation of IKKα in an NBR1-dependent manner, activating the NF-κB pathway and enhancing proinflammatory cytokine expression. In addition, downregulation of SENP6 in microglia effectively reduced cocultured neuronal damage induced by ischaemic stroke. More importantly, we employed an AAV-based technique to specifically knockdown SENP6 in microglia/macrophages, and in vivo experiments showed that SENP6 inhibition in microglia/macrophages notably lessened brain ischaemic infarct size, decreased neurological deficit scores, and ameliorated motor and cognitive function in mice subjected to cerebral ischaemia surgery. Conclusion: We demonstrated a previously unidentified mechanism by which SENP6-mediated ANXA1 de-SUMOylation regulates microglial polarization and our results strongly indicated that in microglia, inhibition of SENP6 may be a crucial beneficial therapeutic strategy for ischaemic stroke. Graphical
- Open Access
Phosphoinositide 3 Kinase γ Plays a Critical Role in Acute Kidney Injury
Inflammatory cells contribute to the pathogenesis of renal ischemia-reperfusion injury (IRI). However, the signaling mechanisms underlying the infiltration of inflammatory cells into the kidney are not well understood. In this study, we examined the effects of phosphoinositide 3 kinase γ (PI3Kγ) on inflammatory cells infiltration into the kidney in response to ischemia-reperfusion injury. Compared with wild-type mice, PI3Kγ knockout mice displayed less IRI in the kidney with fewer tubular apoptotic cell. Furthermore, PI3Kγ deficiency decreased the number of infiltrated neutrophils, macrophages, and T cells in the kidney, which was accompanied by a decrease in the expression of pro-inflammatory cytokines in the kidney. Moreover, wild-type mice treated with AS-605240, a selective PI3Kγ inhibitor, displayed less tubular damage, accumulated fewer inflammatory cells, and expressed less proinflammatory molecules in the kidney following IRI. These results demonstrate that PI3Kγ has a critical role in the pathogenesis of kidney damage in IRI, indicating that PI3Kγ inhibition may serve as a potential therapeutic strategy for the prevention of ischemia-reperfusion-induced kidney injury.
Open AccessPhosphoinositide 3 Kinase γ Plays a Critical Role in Acute Kidney Injury
Inflammatory cells contribute to the pathogenesis of renal ischemia-reperfusion injury (IRI). However, the signaling mechanisms underlying the infiltration of inflammatory cells into the kidney are not well understood. In this study, we examined the effects of phosphoinositide 3 kinase γ (PI3Kγ) on inflammatory cells infiltration into the kidney in response to ischemia-reperfusion injury. Compared with wild-type mice, PI3Kγ knockout mice displayed less IRI in the kidney with fewer tubular apoptotic cell. Furthermore, PI3Kγ deficiency decreased the number of infiltrated neutrophils, macrophages, and T cells in the kidney, which was accompanied by a decrease in the expression of pro-inflammatory cytokines in the kidney. Moreover, wild-type mice treated with AS-605240, a selective PI3Kγ inhibitor, displayed less tubular damage, accumulated fewer inflammatory cells, and expressed less proinflammatory molecules in the kidney following IRI. These results demonstrate that PI3Kγ has a critical role in the pathogenesis of kidney damage in IRI, indicating that PI3Kγ inhibition may serve as a potential therapeutic strategy for the prevention of ischemia-reperfusion-induced kidney injury.